Healthcare -
Drug Manufacturers - Specialty & Generic - NASDAQ - CA
$ 4.08
-12.8 %
$ 224 M
Market Cap
21.47
P/E
1. INTRINSIC VALUE
Balance Sheet
Aurora Cannabis Inc.
| Current Assets | 427 M |
| Cash & Short-Term Investments | 117 M |
| Receivables | 45.4 M |
| Other Current Assets | 264 M |
| Non-Current Assets | 412 M |
| Long-Term Investments | 6.34 M |
| PP&E | 294 M |
| Other Non-Current Assets | 111 M |
| Current Liabilities | 125 M |
| Accounts Payable | 20.3 M |
| Short-Term Debt | 57.2 M |
| Other Current Liabilities | 47.1 M |
| Non-Current Liabilities | 112 M |
| Long-Term Debt | 47.6 M |
| Other Non-Current Liabilities | 64.6 M |
EFFICIENCY
Earnings Waterfall
Aurora Cannabis Inc.
| Revenue | 270 M |
| Cost Of Revenue | 139 M |
| Gross Profit | 131 M |
| Operating Expenses | 178 M |
| Operating Income | -46.5 M |
| Other Expenses | 12.6 M |
| Net Income | -59 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Aurora Cannabis Inc.
| Net Income | -59 M |
| Depreciation & Amortization | 33.1 M |
| Capital Expenditures | -17 M |
| Stock-Based Compensation | 12.7 M |
| Change in Working Capital | -15.6 M |
| Others | -37.2 M |
| Free Cash Flow | -85.5 M |
Wall Street Analysts Price Targets
Aurora Cannabis Inc.
Wall Street analysts predict an average 1-year price target for ACB of $6.67 , with forecasts ranging from
a
low of
$1 to a high of $11 .
ACB Lowest Price Target
Wall Street Target
1 USD
-75.49%
ACB Average Price Target
Wall Street Target
6.67 USD
63.40%
ACB Highest Price Target
Wall Street Target
11 USD
169.61%
4. DIVIDEND
ANALYSIS
ACB does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Aurora Cannabis Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
3 Cannabis Stocks For Investors To Secure For Future Gains
The current state of the cannabis sector has people feeling a type of way. To be more descriptive, those who are invested in marijuana stocks are feeling the backlash of the market. For some time, there has been a sharp decline in the overall trading for most top marijuana stocks. Now, you would think that with the sector down and showing no true signs of recovery, all is lost. That is not the case, as most companies are making money and having a positive impact.
marijuanastocks.com
- 5 days ago
Aurora Cannabis Advises of Second False Article from Investing.com
NASDAQ | TSX: ACB EDMONTON, AB , June 19, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, has become aware of a second instance of misinformation posted on news website, Investing.com. On June 18, 2025, Aurora advised the market that an article posted on Investing.com incorrectly stated that Aurora had agreed to acquire New Zealand-based MedLeaf Therapeutics.
prnewswire.com
- 6 days ago
Aurora Cannabis Denies News of Acquisition of MedLeaf Therapeutics
NASDAQ | TSX: ACB EDMONTON, AB , June 18, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, has become aware of misinformation posted on a news website, incorrectly stating that Aurora has agreed to acquire New Zealand based MedLeaf Therapeutics. The Company has not entered into any such agreement, has had no discussions with MedLeaf Therapeutics with respect to any business combination transaction, and has not made any statement or filed any information pertaining to any such transaction.
prnewswire.com
- 1 week ago
Aurora Cannabis: Poland Headwinds Result In Disappointing Outlook (Rating Downgrade)
Aurora Cannabis reported mixed Q4/FY2025 results, with higher-than-expected revenues offset by lower profitability due to a number of one-time expenses. Following substantial growth in recent quarters, medical cannabis sales were essentially flat on a quarter-over-quarter basis. On the conference call, management admitted to headwinds from recent regulatory changes in Poland. As a result, medical cannabis sales and profitability are expected to decline in Q1/FY2026.
seekingalpha.com
- 1 week ago
Aurora Cannabis Inc. (ACB) Q4 2025 Earnings Call Transcript
Aurora Cannabis Inc. (NASDAQ:ACB ) Q4 2025 Earnings Conference Call June 18, 2025 8:00 AM ET Company Participants Kevin Niland - Corporate Participant Miguel Martin - CEO & Executive Chairman Simona King - Chief Financial Officer Conference Call Participants Derek J. Lessard - TD Cowen, Research Division Frederico Yokota Choucair Gomes - ATB Capital Markets Inc., Research Division Matt Bottomley - Canaccord Genuity Corp., Research Division Pablo Ernesto Zuanic - Zuanic & Associates William Joseph Kirk - ROTH Capital Partners, LLC, Research Division Operator Greetings.
seekingalpha.com
- 1 week ago
Aurora Cannabis Stock Falls as Canadian Producer Expects International Sales to Decline
Aurora Cannabis (ACB) shares tumbled Wednesday as the Canadian cannabis operator said it expects “temporary declines” in its international markets, which include the U.S.
investopedia.com
- 1 week ago
Canadian Medical Marijuana Firm Aurora Cannabis Expects Weak Demand In International Market
Canada-based medical marijuana company Aurora Cannabis Inc.'s ACB stock is trading lower after it released its fourth quarter 2025 earnings.
benzinga.com
- 1 week ago
Aurora Cannabis Shares Fall on Polish Setback, Higher Costs in 4Q
Aurora Cannabis slid Wednesday morning after the company said regulatory headwinds in Poland hit prescription volumes and higher logistics costs pressured margins in the fiscal fourth quarter.
marketwatch.com
- 1 week ago
Aurora Cannabis Inc. (ACB) Misses Q4 Earnings Estimates
Aurora Cannabis Inc. (ACB) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.11 per share a year ago.
zacks.com
- 1 week ago
Aurora Cannabis, Bitdeer Technologies Group And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining more than 50 points on Wednesday.
benzinga.com
- 1 week ago
Aurora Cannabis 4Q Loss Narrows as Medical Cannabis Drives Revenue Beat
Aurora Cannabis's loss narrowed in its fiscal fourth quarter thanks to strong growth in its medical-cannabis business.
marketwatch.com
- 1 week ago
Aurora Cannabis Files Full Year Results and Announces Fiscal 2025 Fourth Quarter
NASDAQ | TSX: ACB Achieves Record Annual Global Medical Cannabis Net Revenue 1 of $244.4 million, representing 39% YoY growth Delivers Record Adjusted EBITDA 1 of $49.7 million, representing 261% YoY growth Generates Annual Positive Free Cash Flow 1 of $9.9 million Sustains Strong Balance Sheet with ~$185.3 million of Cash and Debt-Free Cannabis Business 2 EDMONTON, AB , June 18, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the fourth quarter and fiscal year 2025 periods ending March 31, 2025. "We are pleased to report an exceptional year to our shareholders, highlighted by record annual global medical net revenue1, adjusted EBITDA1, and positive free cash flow1.
prnewswire.com
- 1 week ago
8. Profile
Summary
Aurora Cannabis Inc. ACB
COUNTRY
CA
INDUSTRY
Drug Manufacturers - Specialty & Generic
MARKET CAP
$ 224 M
Dividend Yield
0.00%
Description
Aurora Cannabis Inc. produces, distributes, and sells cannabis and cannabis derivative products in Canada and internationally. It also engages in facility engineering and design, cannabis breeding, research, production, derivatives, product development, wholesale, and retail distribution activities. The company produces various strains of dried cannabis, cannabis oil and capsules, and topical kits for medical patients. It also sells vaporizers; consumable vaporizer accessories; and herb mills for using CanniMed herbal cannabis products, as well as grinders and vaporizer lockable containers. In addition, the company engages in the development of medical cannabis products at various stages of development, including oral, topical, edible, and inhalable products; and operation of CanvasRX, a network of cannabis counseling and outreach centers. Further, it provides patient counselling services; design and construction services; and cannabis analytical product testing services. The company's brand portfolio includes Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, Woodstock, and WMMC. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.
Contact
500 - 10355 Jasper Avenue, Edmonton, AB, T5J 1Y6
https://www.auroramj.com
IPO
Date
July 15, 2014
Employees
1073
Officers
Michelle Lefler
Vice President of Communications & Public Relations
Mr. Ananth Krishnan
Vice President of Capital Markets & Investor Relations
Ms. Simona King CPA
Chief Financial Officer
Mr. Alex Miller
Executive Vice President of Operations & Supply Chain
Mr. Rick Savone
Senior Vice President of Global Government Relations
Ms. Nathalie Clark
Executive Vice President, General Counsel & Corporate Secretary
Dr. Jonathan Page Ph.D.
Senior Science Advisor
Mr. Andre Jerome
Executive Vice President of Global Business Development
Ms. Lori Schick
Executive Vice President of Human Resources
Mr. Miguel Martin
Chief Executive Officer & Executive Chairman